XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the latest episode to discuss the company’s recent receipt of its ISO certification and its rapid point-of-care COVID-19 PCR diagnostic test. “We expect to be in the market very soon, within 30 days, pending European approval right now,” Rogers said. “Testing is highly relevant and will be for many years to come. The virus is endemic. It appears that it will be a forever problem. It will be active at all times for the foreseeable future somewhere in the world, and testing is a major part of managing that situation. The rollout of vaccines will not be uniform across the globe. There will be significant discrepancies, primarily for logistical and economic reasons, between the developing world and the developed world. Any time there’s international travel, and in particular between jurisdictions with disparity of economic comfort or success, there’s going to be this need for ongoing testing.”
To view the full press release, visit https://ibn.fm/XGi0w
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information visit the company’s website at www.xphyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
